financetom
Business
financetom
/
Business
/
Nike Poised for Quarterly Earnings Beat, Guide Third-Quarter Below Street, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nike Poised for Quarterly Earnings Beat, Guide Third-Quarter Below Street, Morgan Stanley Says
Dec 13, 2024 12:52 PM

03:36 PM EST, 12/13/2024 (MT Newswires) -- Nike ( NKE ) is expected to deliver a fiscal second-quarter earnings beat, but guide the third quarter below Wall Street's expectations amid potential downside to sales and gross margin, Morgan Stanley said in a note emailed Friday.

The athletic footwear and apparel maker is scheduled to release second-quarter results Thursday. Morgan Stanley projects earnings at $0.67 a share, which it said would top the Street's $0.65 view, mainly due to selling, general, and administrative expense discipline.

The brokerage sees sales falling 10% year over year versus the Street's call for a 9% decline and Nike's ( NKE ) own outlook range indicating an 8% to 10% drop. Almost all company data points during the period were "incrementally negative," leading to Morgan Stanley's below-consensus sales view, the brokerage said.

The firm expects Nike ( NKE ) to guide third-quarter EPS between $0.55 and $0.60, and sales dropping by high-single-digit to low-double-digit percentage, lagging the Street's projections for $0.65 and a 7% decline, respectively. The brokerage expects "inventory digestion" and sales and promotion pressures to linger in the near term.

Morgan Stanley reduced its price target on the Nike ( NKE ) stock to $80 from $82 while maintaining its equal-weight rating. The company's shares were down 0.8% in Friday late-afternoon trade. The stock has shed 29% in value so far this year.

In September, Nike ( NKE ) said that Elliott Hill would become its chief executive. In October, the company withdrew its full-year guidance given the CEO transition.

Nike ( NKE ) is unlikely to reinstate the outlook amid factors such as Hill's short tenure so far and a lack of clarity around the company's strategy, Morgan Stanley said. The brokerage added that it's doubtful of Nike ( NKE ) and the Street's assumptions that fundamentals could "meaningfully improve" in the second half of the year.

Morgan Stanley cut its full-year EPS outlook to $2.45 from $2.60 and now sees sales decreasing 9% versus its prior projection calling for an 8% decline.

"Altogether, while (Nike's ( NKE )) go-forward strategy is outstanding, (and) there's little evidence of turnaround in the fundamentals, but it also enjoys a new-CEO halo, we think the stock proves mostly range-bound," the brokerage wrote.

Price: 77.32, Change: -0.64, Percent Change: -0.83

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Mar 25, 2026
Merck & Co Inc. ( MRK ) on Wednesday agreed to acquire Terns Pharmaceuticals Inc. ( TERN ) , as the U.S. drugmaker accelerates efforts to offset looming revenue risks tied to its blockbuster cancer immunotherapy Keytruda. The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion. The Financial Times was the first...
Update: Market Chatter: CVS Health Reaches Settlement With FTC on Insulin Pricing
Update: Market Chatter: CVS Health Reaches Settlement With FTC on Insulin Pricing
Mar 25, 2026
11:23 AM EDT, 03/25/2026 (MT Newswires) -- (Updates with replies from CVS Health ( CVS ) and the FTC in the third and fourth paragraphs.) CVS Health ( CVS ) has reached a proposed settlement with the Federal Trade Commission over insulin pricing, Reuters reported Tuesday, citing the company. The company's pharmacy benefit management unit, Caremark, has focused on lowering...
BioCryst Shares Remain Undervalued, RBC Says
BioCryst Shares Remain Undervalued, RBC Says
Mar 25, 2026
11:18 AM EDT, 03/25/2026 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) remains undervalued even with a recent price increase due to unconfirmed reports of being a takeover target, RBC Capital Markets said in a Wednesday note. Even with the shares up 24% year-to-date, RBC's analysis of BioCryst in various takeout scenarios and as an independent company all projected share...
EisnerAmper Announces Continuation Vehicle Transaction with TowerBrook
EisnerAmper Announces Continuation Vehicle Transaction with TowerBrook
Mar 25, 2026
Agreement reflects EisnerAmper's long-term growth potential NEW YORK, March 25, 2026 /PRNewswire/ -- Eisner Advisory Group LLC (EisnerAmper) and TowerBrook Capital Partners L.P. (TowerBrook) announced the completion of a continuation vehicle transaction (CV). Carlyle AlpInvest led the transaction, with funds managed by Hamilton Lane serving as co-lead alongside participation from syndicate investors. EisnerAmper partnered with TowerBrook in 2021, in what was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved